XW04358
Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
Introduce Mosunetuzumab in Central Vein, Perc, New Tech 8
Axis Breakdown
Every ICD-10-PCS code is exactly seven characters, one per axis. Each character's meaning is defined by its position in the code.
| Position | Value | Meaning |
|---|---|---|
| 1 | SectionX | New Technology |
| 2 | Body SystemW | Anatomical Regions |
| 3 | Root Operation0 | Introduction Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |
| 4 | Body Part4 | Central Vein |
| 5 | Approach3 | Percutaneous |
| 6 | Device / Substance / Technology5 | Mosunetuzumab Antineoplastic |
| 7 | New Technology Group8 | New Technology Group 8 |
Contextual Map
Every relationship of XW04358 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
PCS table
- XW0[PCS table]
- [object Object] — Section: [object Object] [Section]: “[object Object]”
- [object Object] — Body System: [object Object] [Body System]: “[object Object]”
- [object Object] — Operation: [object Object] [Operation]: “[object Object]”
Nearest codes
- XW03358 — Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
- XW04308 — Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
- XW04357 — Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
- XW0435A — Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10 [One axis away]
- XW04368 — Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
- XW04378 — Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
- XW04388 — Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
- XW04398 — Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8 [One axis away]
Change history
No changes recorded for this code — unchanged since the FY2026 (April) baseline of the change ledger.